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ABSTRACT
Objective: Diabetes is associated with progression to severe COVID-19. The objective of this study
was to estimate to what extent the increased risk among people with diabetes could impact the sec-
ondary care costs of COVID-19 throughout Europe during the first wave of the COVID-19 pandemic
from January to June 2020.
Methods: Applying a health care cost model based on inputs from data published in international
peer-reviewed journals, identified via a rapid literature review this study aimed to estimate the total
secondary sector costs of COVID-19. Estimates of unit costs were based on data from Denmark,
France, Spain and the UK. We calculated average costs per patient without diabetes and according to
four diabetes categories based on risk of hospitalization, admission to intensive care unit, ventilator
support and length of hospital stay.
Results: The estimated cost per hospital admission during the first wave of COVID-19 in Europe
ranged between EUR 25,018 among people with type 2 diabetes in good glycaemic control to EUR
57,244 among people with type 1 diabetes in poor glycaemic control, reflecting higher risk of inten-
sive care, ventilator support and longer hospital stay according to diabetes category, while the corre-
sponding cost for people without diabetes was estimated at EUR 16,993. The total direct costs of
secondary care of COVID-19 in Europe were estimated at EUR 13.9 billion. Thus, 23.5% of the total
costs accounted for treating people with diabetes.
Conclusions: This study highlights the importance of a greater focus on prevention and adequate
treatment of diabetes and the need for special attention to avoid infection with COVID-19 to the
extent possible among those already diagnosed with diabetes.
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The first confirmed cases of coronavirus disease 2019 (COVID-
19) were reported in Europe on 31 January 20201, and on 11
March 2020, in part due to the rapid escalation of cases in the
European region, the World Health Organization declared the
outbreak of COVID-19 a global pandemic2. In the first half of
2020, COVID-19 has led to more than 2.4 million confirmed
cases in Europe and presumably many more unconfirmed
cases. As of 30 June 2020, 190,000 cases of death associated
with confirmed COVID-19 have been registered in this region3,
however, counting only confirmed deaths due to COVID-19
likely underestimates the number of deaths attributable to the
pandemic4. During the first six months, also referred to as the
first wave, of the pandemic, Europe has experienced higher
prevalence and mortality from COVID-19 compared to many
Asian and African countries5. The difference is partly due to
different lockdown strategies, as an aggressive lockdown strat-
egy has proven effective to reduce both prevalence and mor-
tality of infectious diseases6–8. The downside of a lockdown,
especially for people with diabetes, is that it also impacts rou-
tine visits, which can result in complications that are not dealt
with in a timely manner9,10. Diabetes is the term given to a
group of serious, chronic diseases which are characterized by
hyperglycaemia. The prevalence of diagnosed diabetes in
European adult populations ranges between 4.6% in Ireland
and 14.9% in Portugal; there is a total of 60 million people
with diabetes in Europe, corresponding to a European average
of 9.2%11.
Approximately 10% of people with diabetes have type 1
diabetes, while 90% have type 2 diabetes11. A large propor-
tion of people with diabetes are not achieving good
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glycaemic control, potentially leading to comorbidities e.g.
damage to the heart, blood vessels, kidneys, eyes and
nerves; and dysfunction of the immune system12,13. Due to
compromised immunity, people with diabetes are in general
more susceptible to infection and to the risk of severe out-
comes due to infection. Specifically, with poor glycaemic
control the risk of infections and serious infections rise13,14.
The correlation between diabetes and COVID-19 is not yet
fully understood. No study has, to our knowledge, suggested
that people with diabetes are at higher risk of contracting
COVID-19 infection. However, recent studies suggest that
people with diabetes and poorly controlled blood glucose
who contract COVID-19 are more likely to have severe and
fatal outcomes15–25. This includes higher rates of admission
to hospitals and intensive care units (ICUs) and increased
need of invasive mechanical ventilation (IMV).
Recognizing that people with diabetes are more likely to
experience a more severe course of COVID-19, we aimed to
assess the increased direct hospital costs associated with
treating COVID-19 patients with diabetes throughout Europe.
Moreover, we highlight the consequences of poor glycaemic
control in people with diabetes and the resultant increased
economic burden of treating people with diabetes and
COVID-19.
Methods
This study applied a health care cost model estimating the
direct costs of secondary care (i.e. hospital costs) of COVID-
19 in the first half of 2020 in Europe by the four aforemen-
tioned diabetes categories. Here, Europe is defined as the
countries of EU 27, along with Iceland, Norway, Switzerland,
Liechtenstein and the United Kingdom. Total direct costs of
secondary care were defined as publicly funded hospital ser-
vice usage, including hospital admissions, admissions to ICUs
and support by IMV during ICU stays (henceforth referred to
as ICUþ IMV). Other potential costs such as primary care
costs, i.e. visits to a general practitioner, and indirect costs,
e.g. productivity loss during illness, were not calculated. The
health care cost model applied in this study is based on a
parallel methodology as a health care cost model estimating
the direct costs of secondary care according to BMI catego-
ries. The manuscript for this article is currently in press26.
In the first wave of the pandemic, the number of people test-
ing positive for COVID-19 throughout Europe depended largely
on the testing strategy applied in each country. Therefore, we
used country-specific data for hospital admissions as a starting
point for the health care cost model and did not take into
account COVID-19 patients who were not hospitalized.
To obtain knowledge on the risk of severe disease among
people with diabetes hospitalized due to COVID-19 which
could be used in the health care cost model, a rapid litera-
ture review was performed. We searched PubMed on 1 July
2020 using the key terms “COVID-19” or “coronavirus
infection” or “SARS-CoV-2” and “diabetes”. Peer-reviewed
articles written in English published between 1 January 2020
and 30 June 2020 were included in the initial title and
abstract screening. Articles estimating risk of general
hospitalization, risk of admission to ICU and risk of admission
to ICUþ IMV due to COVID-19 among people with diabetes
were included.
Data published in international peer-reviewed journals
were used as inputs into the health care cost model. We pri-
oritized articles from Europe estimating age- and sex-
adjusted risks. In cases where we identified additional useful
knowledge from other countries, e.g. the US and China,
those were also included.
Input to the health care cost model
Based on the rapid literature review and the identified infor-
mation, we defined the model dimensions regarding groups
of people with diabetes as follows: type 1 diabetes in good
glycaemic control, type 1 diabetes in poor glycaemic control,
type 2 diabetes in good glycaemic control, type 2 diabetes
in poor glycaemic control. Glycaemic control is commonly
assessed by measuring glycated haemoglobin (HbA1c), fast-
ing plasma glucose or 2-h plasma glucose. This study applied
findings on glycaemic control obtained from studies identi-
fied in the rapid literature review as an input to the health
care cost model. Hence, the definition of glycaemic control
applied in the health care cost model ultimately depends on
the definitions applied in the underlying studies that were
identified by the rapid literature review.
To model the population sizes, we applied the estimated
distribution between type 1 and type 2 diabetes from the
International Diabetes Federation (IDF) Diabetes Atlas: 10%
with diabetes type 1 and 90% with type 211. Potentially vary-
ing prevalence rates in different age groups was not consid-
ered in this study. Other types of diabetes e.g. gestational
diabetes, and secondary diabetes are much less common
and were therefore not taken into account for the purpose
of this study.
Estimates of risk of hospitalization, risk of ICU admission
and IMV were obtained from the rapid literature review and
ORs from the literature were adjusted into RRs. For each of
the four diabetes categories, we ensured that the resulting
risk of severe outcomes by diabetes type and glycaemic con-
trol status was coherent with both the reported risk associ-
ated with the type of diabetes and the reported risk
associated with being in good or poor glycaemic control.
Admissions and type of treatment
The distribution and number of people hospitalized were cal-
culated based on the number of people admitted to hospital
for COVID-19 treatment in Europe from 1 January 2020 until
30 June 2020 obtained from27 (720,547) and the increased
risk of hospitalization among people with diabetes compared
to people without diabetes (OR ¼ 1.8 (1.6–2.2)) obtained
from Reilev et al.25. The risk of admission to ICU among hos-
pitalizations was calculated based on data from McKeigue28,
estimating crude RRs of 4.9 (3.3–7.3) and 2.6 (2.3–2.9) for
people with type 1 diabetes and type 2 diabetes, respect-
ively, compared with people without diabetes. Thus, not dis-
tinguishing between good and poor glycaemic control. Risks
2 S. C. BAIN ET AL.
of treatment in ICU, including IMV, were calculated based on
data from Smith et al.29 estimating that the crude rate for
people with diabetes in poor glycaemic control was signifi-
cantly higher compared with people in good glycaemic con-
trol (31.5 vs. 17.8%; p¼.045), thus assuming the same risk for
people with diabetes in good/poor glycaemic control inde-
pendent of type of diabetes. Here, poor glycaemic control
was defined as having HbA1C 7.5% measured in hospital29.
Unit costs
Publicly available cost data from Denmark, France, Spain and
the UK were used to estimate costs of hospitalization, admis-
sion to ICU and treatment via ICUþ IMV30–37. For the remain-
ing 28 countries, costs were estimated using a cost index
from Eurostat based on per capita costs for inpatient curative
and rehabilitative care38.
All results are presented in euros (EUR, 2020 price level).
Cost estimates from Denmark and the UK were converted to
EUR using an exchange rate (as of 18 June 2020) of 1.11 for
pounds sterling (GBP) and 0.13 for Danish krone (DKK).
Health care cost model
The health care cost model determined the cost per patient
and the total direct costs of secondary care by country and
diabetes category (Figure 1). By adding the country-specific
costs across diabetes categories and countries, one can esti-
mate the total estimated costs of secondary care of COVID-
19 in Europe and for people with diabetes.
The total direct costs of secondary care were calculated
from the costs per patient and the number of admitted
patients by country and diabetes category. The number of
admitted patients was estimated by multiplying the number
of admissions due to COVID-19 per country, the relative risk
of hospital admission with COVID-19 by diabetes category
and the distribution of population by diabetes category
and country.
The costs per patient by diabetes category and country
were calculated by multiplying the cost per bed day by
country and the average number of bed days per admitted
patient. The average number of bed days was estimated by
multiplying the risk of admission to ICU and ICUþ IMV by
diabetes category, and the expected number of bed days in
general hospital, ICU and ICUþ IMV when admitted to the
specific unit by diabetes category.
Results
Rapid literature review
Initially, 803 articles were identified (Figure 2). During title
and abstract screening, 26 of the 803 publications were
selected for full-text review, and 15 were included in the
rapid review. Articles that did not estimate relevant out-
comes (see method section) and articles not peer-reviewed
were excluded during the review.
Seven of the included studies were from Europe and nine
were from US or China. Three studies were systematic
reviews while the rest were either cohort studies or case-con-
trol studies including between 174 and 23,804 COVID-19
patients. In Supplementary Table 1, an overview of the stud-
ies identified in the rapid literature review is presented.
Admissions and type of treatment
Based on the increased risk of hospitalization due to COVID-
19 among people with diabetes, we estimated that 1.4% of
all patients admitted to hospital with COVID-19 had type 1
diabetes and 12.4% had type 2 diabetes. Table 1 summarizes
the modelled distribution of people in the four diabetes cat-
egories, and the modelled distribution and number of people
with diabetes among patients hospitalized with COVID-19.
Applying the risk of admission to ICU, Table 2 shows the
resulting calculated risks of all four diabetes categories and
for people without diabetes. It shows that people with dia-
betes had a 24.6–75.8% estimated risk of admission to ICU
depending on type of diabetes and glycaemic control, while
people without diabetes had a 13.3% risk of ICU admission25.
We estimated that 15% (110,151) of the admitted patients
are admitted to ICU, and of these, 20% (22,136) are people
with diabetes. We further estimated that 10% (75,533) will
need ventilation during their ICU admission, and hereof, 20%
(15,154) are people with diabetes (for country-specific admis-
sions, see Supplementary Table 5). Table 2 further shows
that 11.9–55.9% of people with diabetes who were admitted
to hospital received ICUþ IMV treatment. The corresponding
rate for people without diabetes was 9.1%.
Cost per bed type
The average weighted cost per diem (24 h) across all
European countries for admission to general hospital, ICU
and ICUþ IMV were EUR 883, EUR 1925 and EUR 3183,
respectively.
Country-specific costs for all countries are presented in
Supplementary Table 2.
Cost per average hospital admission according to
diabetes category
Table 3 shows the modelled cost per average hospital admis-
sion for the four different diabetes categories and the refer-
ence group (no diabetes). The average cost across all
countries ranges from EUR 16,993 for treating people with-
out diabetes to EUR 57,244 for treating people with diabetes
type 1 in poor glycaemic control. The country-specific mod-
elled average costs per patient are presented in
Supplementary Table 3.
Risk of ICU admission was higher for people with diabetes
and especially for people with diabetes in poor glycaemic
control. Since admission to ICU was significantly more expen-
sive than a general hospital admission, the costs per average
hospital admission due to COVID-19 were considerably
higher for people with diabetes in poor glycaemic control
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compared with people with diabetes in good gly-
caemic control.
Based on the calculated absolute costs per patient pre-
sented in Table 3, Table 4 reports relative costs showing that
the average hospital cost of treating a person with type 1
diabetes in poor glycaemic control was 97% higher than the
average hospital cost of treating a person with type 1
diabetes in good glycaemic control (i.e. 57,244/28,997 EUR).
Moreover, Table 4 shows that the average hospital cost of
treating a person with type 2 diabetes in poor glycaemic
control was 84% higher than the average hospital cost of
treating a person with type 2 diabetes in good glycaemic
control (i.e. 46,130/25,018 EUR). Finally, it shows that the
average hospital cost of treating a person with diabetes was
M
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Figure 1. Economic model outline.
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103% higher than the hospital cost of treating a person with-
out diabetes.
Total direct secondary care costs
The direct costs of secondary care of COVID-19 in Europe
reported in Table 5 were estimated by summing the coun-
try-specific total direct costs of secondary care (reported in
Supplementary Table 4) with a resulting estimated total cost
of EUR 13.9 billion. The total costs of treating people with
diabetes were EUR 3.3 billion, while the total costs of treat-
ing people without diabetes were 10.6 billion. Treatment in a
medical department accounted for more than half of the
total costs, ICU treatment without IMV accounted for 15%
and ICUþ IMV treatment accounted for one-third of the
total costs.
The total direct costs of secondary care of COVID-19 asso-
ciated with type 1 diabetes were estimated at EUR 0.5 billion,
which corresponds to 3.4% of the total costs (Table 6).
Likewise, the costs associated with type 2 diabetes were esti-
mated at EUR 2.8 billion, accounting for 20.20% of the total
costs. In comparison, the estimated prevalence of type 1 and
type 2 diabetes in the European population is 0.9 and 8.3%,
respectively. Moreover, the estimated costs of treating peo-
ple with diabetes in good glycaemic control accounted for
10.2%, while the share of people with diabetes in good
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Figure 2. Flow chart for the rapid literature search.
Table 2. Percentage of people admitted to ICU and ICUþ IMV, compared with all people admitted to hospital with COVID-19, for each diabetes category and
for people without diabetes.
Type 1 diabetes Type 2 diabetes No diabetes








15.3 55.9 11.9 43.1 9.1
Note: Crude estimates from the literature were converted to shares within each diabetes category.
aRate of admission to ICU for people with diabetes were obtained from McKeigue et al.28 and from Reilev et al.25 for people without diabetes.
bRate of treatment in ICU including IMV were obtained from Smith et al.24.
cThe risk of admission to ICU among hospitalizations was calculated based on data from crude RRs for people with type 1 diabetes and type 2 diabetes, respect-
ively, compared with people without diabetes. Thus, not distinguishing between good and poor glycaemic control. Risks of treatment in ICU, including IMV,
were calculated based on the crude rate for people with diabetes in poor glycaemic control that was significantly higher compared with people in good gly-
caemic control, thus assuming the same risk for people with diabetes in good/poor glycaemic control, independent of type of diabetes.
Abbreviations. ICU, intensive care unit; IMV, invasive mechanical ventilation.
Table 1. Input parameters regarding number of hospitalizations due to COVID-19 in Europe across four diabetes categories and for people without diabetes.













0.4 1.0 7.5 4.4 13.2 86.8 100
Total number of people
hospitalized in Europe (N),
January–June 2020c
2656 6869 54,028 31,701 95,255 625,292 720,547
aDiabetes prevalence in the European population was based on data from the IDF Diabetes Atlas11, McKnight et al.39, and de Pablos-Velasco et al.40
bThe distribution of hospitalization were calculated based on Reilev et al.25
cTotal number of people hospitalized in Europe was based on data from the University of Washington Institute for Health Metrics and Evaluation27. The distribu-
tion of number of people hospitalized between diabetes categories were calculated based on IDF diabetes Atlas11 and risk of hospitalization obtained from
Reilev et al.25.
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glycaemic control in the European population is 5.4%.
Treatment of people with diabetes in poor glycaemic control
cost EUR 1.9 billion, which is 13.4% of the total costs, while
the prevalence of people with diabetes in poor glycaemic
control in the European population is only 3.8% (Table 6).
The disproportional factor for share of costs were hence 3.7,
2.4, and 3.6 times compared to the prevalence in the popula-
tion for the three groups, respectively.
Alternative scenarios
The total costs were driven by people with diabetes having
additional risk of hospital admission and increased risk of
severe outcomes while in hospital, leading to higher rates of
admission to ICU and ICUþ IMV and to longer hospital stays
overall. If people with diabetes had the same risk of being
admitted to hospital, to ICU and to ICUþ IMV as those with-
out diabetes, the total direct secondary care costs of COVID-
19 in Europe would have been EUR 12.5 billion, or EUR 1.3
billion lower than was the case with the increased risk.
If people with type 2 diabetes had the same risk of being
admitted to hospital and admitted to ICUþ IMV as those
without diabetes, the total direct secondary care costs of
COVID-19 in Europe would have been EUR 12.6 billion. The
health care costs are hence 10.7% higher than they would
have been if people with type 2 diabetes had the same risk
of severe COVID-19 as people without type 2 diabetes.
Sensitivity analysis
Since COVID-19 is a novel disease, there is still much uncer-
tainty related to calculating the true secondary sector health
Table 3. Cost (EUR) per patient of an average hospital stay, by diabetes category and for people without diabetes.
Type 1 diabetes Type 2 diabetes No diabetes
Good glycaemic control Poor glycaemic control Good glycaemic control Poor glycaemic control
Denmark 34,011 77,074 27,874 60,026 18,883
France 24,224 46,439 21,058 37,644 14,287
Spain 29,031 58,579 24,984 47,121 17,026
United Kingdom 31,489 62,115 27,124 49,990 18,398
Average (weighted) 28,997 57,244 25,018 46,130 16,993
Note: The cost (EUR) of the average hospital stay by diabetes category per patient is modelled on the RR for general hospital admission, ICU and ICUþ IMV.
Abbreviations. EUR, euro; RR, risk ratios; ICU, intensive care unit; IMV, invasive mechanical ventilation.
Table 4. Relative costs for diabetes categories.
Type 1 diabetes Type 2 diabetes All (weighted) diabetes
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Note: The relative costs were calculated from Table 3.
Table 5. Total costs (EUR, millions) of COVID-19 in Europe, by diabetes category and type of admission.















Total 77 392 1,339 1,467 3,275 10,634 13,908
Medical department 38 99 772 458 1,367 6,159 7,527
ICU 17 90 228 278 612 1,445 2,057
ICUþ IMV 22 204 339 731 1,295 3,029 4,325
Abbreviations. EUR, euro; ICU, intensive care unit; IMV, invasive mechanical ventilation.
Table 6. Total costs, cost share and prevalence in European population for people without diabetes, with type 1 diabetes, with type 2 diabetes, with diabetes














469 2806 1416 1859 3275 10,634 13,908
Cost share (%) 3.4 20.2 10.2 13.4 23.5 76.5 100
Prevalence (%) 0.9 8.3 5.4 3.8 9.2 90.8 100
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care costs. The results represent the most likely single point
estimate; however, we have also computed lower and upper
bound estimates for the total cost. The range for total direct
secondary care costs is EUR 10.8–21.3 billion. The lower esti-
mate reflects a reduced risk of hospitalization (RR: 1.54) and
reduced risk of ICU for people with diabetes across diabetes
groups (2.06–3.26), but an unchanged increased risk of venti-
lator treatment25,28,41. The estimate also includes a 20%
decrease in per diem costs across admission type (regular,
ICU and ICUþ IMV), whereas the high estimate reflects an
increased risk of hospitalisation (RR: 2.03) and increased risk
of ICU for people with diabetes across diabetes groups
(2.06–7.31), but an unchanged increased risk of ventilator
treatment25,28,41. The estimate also includes a 20% increase
in per diem costs across admission type (regular, ICU
and ICUþ IMV).
Discussion
To our knowledge, no other study has investigated the
impact of the increased risk of severe disease course of
COVID-19 among people with diabetes on the costs of sec-
ondary care of COVID-19 treatment throughout Europe.
In this study, we found that both type 1 and type 2 dia-
betes and poorly controlled diabetes is associated with
excess costs of treating people for COVID-19 in selected
countries in Europe.
We estimated that people with type 1 diabetes accounted
for 3.4% of the total costs of treating people hospitalized for
COVID-19 in the first half of 2020 despite comprising only
0.9% of the population. People with type 2 diabetes
accounted for 20.2% of the total costs of treating people for
COVID-19 and make up only 8.3% of the population.
Furthermore, people with poorly controlled diabetes were at
higher risk for severe outcomes associated with COVID-19,
resulting in increased secondary care costs. People with dia-
betes who were in poor glycaemic control accounted for
13.4% of the total costs of treating people for COVID-19 des-
pite constituting only 3.8% of the population. Our study
therefore supplements current well-established knowledge
that poorly controlled diabetes is costly42–44.
Although data regarding the association of COVID-19 and
diabetes control is limited, previous studies, investigating the
association of diabetes control and other infections such as
SARS and influenza have suggested that people with dia-
betes in poor glycaemic control have an increased risk of
complications45,46, in line with the findings of the association
between COVID-19 and diabetes control.
Studies of COVID-19 and diabetes have indicated that
people with diabetes have an increased risk of requiring
admission to ICU and treatment via ICUþ IMV compared
with people without diabetes; however, to our knowledge
no studies have indicated that people with diabetes have a
higher or lower risk of acquiring COVID-19. The magnitude
of any such increased or decreased risk has not been estab-
lished and, therefore, it was not considered in this study.
Thus, the only cost driver of the present study was increased
risk of severe outcomes due to COVID-19, i.e. risk of
hospitalization, risk of admission to ICU, treatment via
ICUþ IMV and a prolonged hospital stay for people with dia-
betes while in hospital for COVID-19 treatment.
Other possible cost drivers are comorbidities and compli-
cations among people with diabetes. People with diabetes
and comorbidities are expected to have more severe out-
comes of COVID-19 compared to people with diabetes with-
out comorbidities. This will drive up costs for people with
diabetes and comorbidities due to longer stay time in hos-
pital and because people will most likely need treatment for
one or more of the comorbidities and COVID-19 simultan-
eously. We have not explicitly included factors related to
comorbidities in the cost model, since other studies find that
there is a strong link between diabetes in poor glycaemic
control and comorbidities and/or complications; hence, those
people may also be more likely to experience more severe
outcomes of COVID-1947. Since much of the risk for severe
outcomes of COVID-19 is included in the outcomes for poor
glycaemic control, we do not include the independent con-
tributions from comorbidities and complications, since this
would result in a high risk of double counting. It could, how-
ever, contribute further to the precision of the cost estimates
if the factors were examined separately.
A number of additional factors could potentially increase
the costs of hospital admissions due to COVID-19. The health
care cost model in the present study included only costs on
usual admissions to general hospital or ICU. However, during
the COVID-19 pandemic, hospitals have created special
COVID-19 units or transformed other hospital beds to ICU
beds with requirements that could be associated with higher
costs. Moreover, this study calculated only direct costs of
secondary care of COVID-19. However, the total costs of
COVID-19 would be even higher if primary care costs and
indirect costs (e.g. loss of productivity during illness, out-
patient costs during the recovery phase) were included.
Some studies have indicated that people with diabetes
have a significantly higher mortality rate due to COVID-19
compared with people without diabetes20,21,25. Specifically, a
study from the UK found that people with type 1 diabetes
had more than a threefold mortality risk compared with peo-
ple without diabetes, while people with type 2 diabetes had
a twofold mortality risk21. These results support our finding
that type 1 diabetes is associated with more severe out-
comes from COVID-19 than type 2 diabetes. Although the
increased risk of mortality was not included in the health
care cost model in this study, naturally the risk of fatal out-
comes could potentially impact the direct and indirect costs
of COVID-19.
The pandemic has to a large degree paused the health
care system and thereby, for example, reduced the number
of routine assessments for people with diabetes but without
COVID-1948. It remains to be seen whether the long-term
effect of this will worsen health outcomes for people with
diabetes. In order to mitigate worse diabetes control due to
the lockdown measures during the pandemic and at the
same time protect people with diabetes against being
infected, one could implement a greater use of new technol-
ogies such as telemedicine, arrange for supplies of medicines
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to be readily and routinely available and make use of online
communication platforms and other measures to address key
issues such as diagnosis/monitoring and adherence.
The COVID-19 pandemic has had a great impact on public
health and the health care systems throughout Europe dur-
ing the first half of 2020. But the pandemic was far from
over3, and several epidemiology experts anticipated the
second wave of COVID-19 infections49 which we have seen
occur. The number of infections and deaths have increased
throughout Europe once again in the autumn of 20203. Our
study suggests that diabetes contributes significantly to the
cost of COVID-19 care. Both the costs and the number of
people dying from COVID-19 would potentially be lower if
diabetes were prevented to a higher extent than it currently
is and, specifically, if more people with diabetes were in
good glycaemic control across all European countries.
Strengths and limitations
The results presented in this study were based on the cur-
rent carefully selected, recently published peer-reviewed
studies regarding severe outcomes of COVID-19 for selected
European countries. The study was based on a large sample
of data for hospital admissions across Europe and validated
cost data from the four reference countries. However, the
risk of severe outcomes among people with diabetes is not
yet fully understood. The inputs to the health care cost
model from the rapid literature review were not completely
adjusted for confounding factors, and it cannot, therefore, be
stated whether diabetes is an independent risk factor related
to the severe outcomes of COVID-19, or whether it is a con-
founding factor. Evaluation of cost is limited to the four cate-
gories of type 1 and type 2 diabetes in good or poor
glycaemic control and does not include information about
complications and comorbidities of diabetes, which could
likely influence the cost evaluation. Due to the novelty of
COVID-19, most of the existing literature on diabetes and
COVID-19 does not distinguish between type 1 and type 2
diabetes nor is an explicit age distribution available. The
health care cost model therefore applied the estimated distri-
bution between type 1 and type 2 diabetes from the
International Diabetes Federation (IDF) Diabetes Atlas: 10%
with diabetes type 1 and 90% with type 211. Additionally, dif-
ferent definitions of good and poor glycaemic control were
applied across publications. As a result, application of these
estimates to other European countries should be done with
caution. To further improve the study, one could base the
input on observation data and subsequent cost calculation.
This could improve the accuracy of the utility use of COVID-
19 patients across the four diabetes categories, but since it is
still a novel disease, there were no such data available.
In conclusion, this study reports that the average cost of
secondary care for people with diabetes and COVID-19 is
higher compared with people with COVID-19 without dia-
betes. Moreover, this study highlights the importance of
greater focus on prevention and adequate treatment of dia-
betes and the need for special attention to avoid infection
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